Primary Hyperoxaluria Type 1
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Primary Hyperoxaluria Type 1

What is the definition of Primary Hyperoxaluria Type 1?
Primary hyperoxaluria type 1 (PH1) is a rare disorder that mainly affects the kidneys. It results from buildup of a substance called oxalate, which normally is filtered through the kidneys and excreted in the urine. In people with PH1, the accumulated oxalate is deposited in the kidneys and urinary tract. It combines with calcium, forming the main component of kidney and bladder stones (calcium oxalate). Signs and symptoms of PH1 vary in severity and may begin any time from infancy to early adulthood. Symptoms may include recurrent kidney stones; blood in the urine; and urinary tract infections. PH1 is due to genetic changes in a gene called AGXT. Inheritance is autosomal recessive.
What are the alternative names for Primary Hyperoxaluria Type 1?
  • Primary hyperoxaluria type 1
  • Alanine-glyoxylate aminotransferase deficiency
  • Glycolic aciduria
  • HP1
  • Hepatic AGT deficiency
  • Oxalosis 1
  • Peroxisomal alanine glyoxylate aminotransferase deficiency
  • Serine pyruvate aminotransferase deficiency
Who are the top Primary Hyperoxaluria Type 1 Local Doctors?
Elite in Primary Hyperoxaluria Type 1
Elite in Primary Hyperoxaluria Type 1
Referral may be required
Groupement Hospitalier Est, 
Bron, FR 

Pierre Cochat practices practicing medicine in Bron, France. Mr. Cochat is rated as an Elite expert by MediFind in the treatment of Primary Hyperoxaluria Type 1. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Primary Hyperoxaluria, Nephrocalcinosis, Primary Hyperoxaluria Type 1, Kidney Transplant, and Liver Transplant.

Elite in Primary Hyperoxaluria Type 1
Elite in Primary Hyperoxaluria Type 1
Referral may be required
Shmuel Bait Street 12, 9103102, 
Jerusalem, JM, IL 

Yaacov Frishberg practices practicing medicine in Jerusalem, Israel. Mr. Frishberg is rated as an Elite expert by MediFind in the treatment of Primary Hyperoxaluria Type 1. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Primary Hyperoxaluria Type 1, Primary Hyperoxaluria, Nephrocalcinosis, Calcinosis, and Kidney Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Primary Hyperoxaluria Type 1
Elite in Primary Hyperoxaluria Type 1
Referral may be required

Mayo Clinic-Rochester

200 1st St SW, 
Rochester, MN 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

John Lieske is a Nephrologist practicing medicine in Rochester, Minnesota. Dr. Lieske is rated as an Elite provider by MediFind in the treatment of Primary Hyperoxaluria Type 1. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Kidney Stones, Nephrocalcinosis, Primary Hyperoxaluria, Kidney Transplant, and Nephrectomy. Dr. Lieske is currently accepting new patients.

What are the latest Primary Hyperoxaluria Type 1 Clinical Trials?
A Randomized, Double-blind, Placebo-controlled Study Followed by a Treatment Extension to Evaluate the Efficacy and Safety of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1

Summary: This study will be conducted to evaluate the efficacy and safety of YOLT-203 in children and adults with Primary Hyperoxaluria Type 1. After the initial randomized, 6-month double-blind, placebo-controlled period, participants who were initially assigned to placebo will receive a single-dose of YOLT-203 treatment whereas participants in the YOLT-203 group will receive a single-dose of placebo infu...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase I Exploratory Study of YOLT-203 in Patients With Primary Hyperoxaluria Type 1 (PH1)

Summary: This is a single-arm, open-label, single-dose dose-escalation study. It aims to evaluate the safety and tolerability of YOLT-203 in Chinese patients with Primary Hyperoxaluria Type 1 (PH1), and to preliminarily assess the effect of a single administration of YOLT-203 on 24-hour urinary oxalate excretion. The clinical trial will first evaluate the safety and tolerability in adult patients. After th...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center